General Information of Drug (ID: DM27RXS)

Drug Name
ORIN1001 Drug Info
Indication
Disease Entry ICD 11 Status REF
Metastatic breast cancer 2C6Y Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM27RXS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US9040714, 7 DM53Z4I N. A. N. A. Patented [3]
T8361 DM86BDS N. A. N. A. Patented [4]
US8614253, 29-1 DMJKFVU N. A. N. A. Patented [5]
US8614253, 32-5 DMSQODK N. A. N. A. Patented [4]
US8614253, 29-19 DMVI83P N. A. N. A. Patented [6]
879325-11-8 DMP04Z6 N. A. N. A. Patented [3]
AC1LE05K DMPOR3G N. A. N. A. Patented [7]
US8614253, 32-4 DMRSP2M N. A. N. A. Patented [6]
BB 0223767 DM2DT6L N. A. N. A. Patented [4]
US9241942, 32-12 DM8GW54 N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endoplasmic reticulum to nucleus signaling 1 (ERN1) TTOJ9QL ERN1_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03950570) ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Orinove.
3 IRE-1 inhibitors. US9040714.
4 IRE-1 inhibitors. US8614253.
5 IRE-1 inhibitors. US9241942.
6 IRE-1 inhibitors. US9493435.
7 IRE-1 inhibitors. US9693992.